news
SourceOne Debuts LysOmega to Carry DHA Past the Blood-Brain Barrier
SourceOne Global Partners launched LysOmega, a targeted omega-3 formulation developed over four years to bypass the blood-brain and blood-retina barriers. The delivery system aims to solve notoriously poor neural uptake of standard fish oil DHA and EPA.
SourceOne Global Partners launched LysOmega, a targeted omega-3 formulation developed over four years to bypass the blood-brain and blood-retina barriers. The delivery system aims to solve notoriously poor neural uptake of standard fish oil DHA and EPA.
The architecture take
I spent years swallowing generic fish oil capsules under the lazy assumption that higher blood levels automatically translated into better brain cognition. They do not. Standard triglyceride and ethyl ester forms mostly bounce off the blood-brain barrier because neural tissue relies on specialized transporters like Mfsd2a, which preferentially clear lyso-phospholipids. That physiological bottleneck is why high-dose omega-3 trials for mood or cognitive decline regularly throw contradictory results. SourceOne spent four years packaging DHA into this lysophosphatidylcholine-friendly format, and every longevity brand selling nootropics will scramble to license it. The shift moves omega-3s out of blunt heart-health dosing and into precision neurology. My eye is on whether finished supplement brands price this at an absurd premium (they probably will) or prove it raises brain tissue saturation faster than standard krill oil. Either way, simple fish oil feels antiquated.